Citadel Advisors
GSK icon

Citadel Advisors’s GSK GSK Stock Holding History

Citadel Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.2M Sell
691,400
-28,700
-4% -$1.56M 0.01% 1608
2025
Q4 		$35.3M Sell
720,100
-451,900
-39% -$21.1M 0.01% 1751
2025
Q3 		$50.6M Buy
1,172,000
+71,100
+6% +$2.78M 0.01% 1367
2025
Q2 		$42.3M Buy
1,100,900
+264,100
+32% +$10.1M 0.01% 1363
2025
Q1 		$32.4M Sell
836,800
-37,800
-4% -$1.38M 0.01% 1517
2024
Q4 		$29.6M Sell
874,600
-74,000
-8% -$2.66M 0.01% 1755
2024
Q3 		$38.8M Buy
948,600
+238,300
+34% +$9.75M 0.01% 1453
2024
Q2 		$27.3M Buy
710,300
+88,400
+14% +$3.72M 0.01% 1690
2024
Q1 		$26.7M Buy
621,900
+59,520
+11% +$2.45M 0.01% 1787
2023
Q4 		$20.8M Sell
562,380
-37,380
-6% -$1.34M ﹤0.01% 1971
2023
Q3 		$21.7M Buy
599,760
+58,360
+11% +$2.07M ﹤0.01% 1773
2023
Q2 		$19.3M Sell
541,400
-118,840
-18% -$4.26M ﹤0.01% 1926
2023
Q1 		$23.5M Sell
660,240
-375,520
-36% -$13.1M 0.01% 1769
2022
Q4 		$36.4M Sell
1,035,760
-282,440
-21% -$9.41M 0.01% 1382
2022
Q3 		$38.8M Buy
1,318,200
+189,080
+17% +$7.17M 0.01% 1259
2022
Q2 		$61.4M Buy
1,129,120
+839,840
+290% +$46.4M 0.02% 868
2022
Q1 		$15.8M Sell
289,280
-366,240
-56% -$19.9M ﹤0.01% 2292
2021
Q4 		$36.1M Sell
655,520
-130,000
-17% -$6.76M 0.01% 1443
2021
Q3 		$37.5M Buy
785,520
+77,680
+11% +$3.9M 0.01% 1345
2021
Q2 		$35.2M Buy
707,840
+339,600
+92% +$16.3M 0.01% 1444
2021
Q1 		$16.4M Buy
368,240
+72,880
+25% +$3.31M ﹤0.01% 2227
2020
Q4 		$13.6M Buy
295,360
+167,280
+131% +$7.68M ﹤0.01% 2245
2020
Q3 		$6.03M Sell
128,080
-173,200
-57% -$8.68M ﹤0.01% 2891
2020
Q2 		$15.4M Buy
301,280
+95,120
+46% +$4.88M 0.01% 1747
2020
Q1 		$9.76M Buy
206,160
+960
+0.5% +$51.2K ﹤0.01% 1884
2019
Q4 		$12.1M Buy
205,200
+4,640
+2% +$258K 0.01% 2011
2019
Q3 		$10.7M Buy
200,560
+50,880
+34% +$2.62M 0.01% 2139
2019
Q2 		$7.49M Sell
149,680
-25,920
-15% -$1.3M ﹤0.01% 2538
2019
Q1 		$9.17M Buy
175,600
+11,600
+7% +$580K ﹤0.01% 2179
2018
Q4 		$7.83M Sell
164,000
-126,720
-44% -$6.24M ﹤0.01% 2181
2018
Q3 		$14.6M Buy
290,720
+86,640
+42% +$4.4M 0.01% 1697
2018
Q2 		$10.3M Buy
204,080
+24,320
+14% +$1.22M 0.01% 1895
2018
Q1 		$8.78M Buy
179,760
+37,520
+26% +$1.75M ﹤0.01% 1856
2017
Q4 		$6.31M Buy
142,240
+43,280
+44% +$2M ﹤0.01% 2196
2017
Q3 		$5.02M Buy
98,960
+26,960
+37% +$1.37M ﹤0.01% 2304
2017
Q2 		$3.88M Sell
72,000
-9,840
-12% -$525K ﹤0.01% 2383
2017
Q1 		$4.31M Buy
81,840
+49,760
+155% +$2.52M ﹤0.01% 2190
2016
Q4 		$1.54M Sell
32,080
-35,440
-52% -$1.75M ﹤0.01% 3271
2016
Q3 		$3.64M Sell
67,520
-58,400
-46% -$3.2M ﹤0.01% 2294
2016
Q2 		$6.82M Buy
+125,920
New +$6.63M 0.01% 1554

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors's GSK Position: Q1 2026 in Review

Citadel Advisors sold out of GSK (GSK) in Q1 2026, closing a stake of 214,099 shares — an estimated $11.6M sold.

Citadel Advisors first reported a position in GSK in Q2 2013 and held it in 47 quarters. The position peaked at $109M in Q3 2022. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Citadel Advisors reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 214,099 GSK shares in Q1 2026, an estimated $11.6M.
  • Citadel Advisors first reported a position in GSK in Q2 2013 and held it in 47 quarters.
  • Citadel Advisors's GSK position peaked at $109M in Q3 2022.
  • 1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.